The size of the Europe Advanced Infusion Systems Market is estimated to be growing at a prominent rate between 2021 to 2026.
The market is projected to be fuelled by the increasing prevalence of chronic diseases such as cancer and diabetes are driving the European advanced infusion systems market growth. Also, the growing population and associated lifestyles are influencing the market growth. The increasing demand for accurate diagnosis and the technological advancements in the healthcare sectors is expected to boost the market growth as it minimizes user-related risks.
Other factors such as advancing the healthcare sector, growing awareness, and high healthcare expenditure contribute to market growth. Additionally, the market is anticipated to witness significant growth during the forecast period due to its beneficial factors such as higher bioavailability, better safety, limited risk, and therapeutic effectiveness.
Volumetric and syringe pumps and infusion devices utilized in the clinical and surgical industries have been widely used for intravenous therapy throughout the previous few decades. According to industry estimates, 80 percent of hospitalized patients receive intravenous treatment. This demand is likely to rise over the next few years.
In Europe, the senior population is considered one of the significant growth influential factors. The aging population is more susceptible to various chronic diseases such as cancer and diabetes, and other diseases.
However, alternative infusion systems' availability and lack of trained, intelligent systems restrain the market growth. Also, the stringent medical regulations and tariff policies further hamper market growth.
This research report on the Europe Advanced Infusion Systems Market is segmented & sub-segmented into the following categories:
By Application Type:
By Product Type:
By End-Users:
By Country:
Geographically, Europe held the second-largest share of the global advanced infusion systems market in 2020, and it is most likely to continue its growth during the forecast period. The emerging countries in the region such as Germany, Italy, the UK, France, and Spain are significantly uplifting the market growth. Furthermore, as malnutrition rates rise in emerging countries such as UK, Italy, and France, the demand for infusion pumps for vital nutrition is likely to increase. As a result, hospitals are expected to be the leading end-users of infusion systems, accounting for more than half of the market. Key strategies by the major players in the market are expanding the regional market growth.
Germany commands the majority share of the market, and it is anticipated to register a predominant share during the forecast period. The proliferation of chronic diseases like cancer, diabetes, advanced healthcare facilities, and high healthcare spending significantly propels the market growth.
The UK is most likely to witness a significant share in the market because factors such as the growing geriatric population, high prevalence of diabetes, and availability of well-established healthcare infrastructure are fuelling the market growth.
On the other hand, emerging countries such as Italy, France, and Spain are projected to showcase promising shares in the market during the forecast period. The rising incidence of disorders due to the growing population in these countries contributes to the advanced infusion systems market. As a result, the Hospitals are witnessing significant growth over the years. In addition, increasing malnutrition is estimated to surge the demand for infusion pumps for critical nutrition.
KEY MARKET PLAYERS:
Hospira, Inc. is a market leader in infusion technologies globally. The major players in these markets are AngioDynamics, Inc., Medtronic, Inc., Terumo Corporation, Johnson & Johnson, CareFusion Corporation, Animas Corporation, Baxter International, Inc., B. Braun Melsungen AG, I-Flow Corporation, and F. Hoffmann-La Roche Ltd.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Clinical Nutrition
5.1.3 Chemotherapy
5.1.4 Pain Management
5.1.5 Diabetes
5.1.6 Asthma
5.1.7 Y-o-Y Growth Analysis, By Application
5.1.8 Market Attractiveness Analysis, By Application
5.1.9 Market Share Analysis, By Application
5.2 Product
5.2.1 Introduction
5.2.2 Disposable Infusion System
5.2.3 Elastomeric Infusion System
5.2.4 Ambulatory Infusion System
5.2.5 Volumetric Infusion System
5.2.6 Patient Controlled Analgesia Pump
5.2.7 Syringe Infusion System
5.2.8 Implantable Infusion System
5.2.9 Y-o-Y Growth Analysis, By Product
5.2.10 Market Attractiveness Analysis, By Product
5.2.11 Market Share Analysis, By Product
5.3 End-User
5.3.1 Introduction
5.3.2 Diagnostic Centers
5.3.3 Hospitals
5.3.4 Ambulatory Surgical Centers
5.3.5 Y-o-Y Growth Analysis, By End-User
5.3.6 Market Attractiveness Analysis, By End-User
5.3.7 Market Share Analysis, By End-User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product
6.1.3.4 By End-User
6.1.4 Market Attractiveness Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product
6.1.3.4 By End-User
6.1.5 Market Share Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product
6.1.3.4 By End-User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Hospira, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AngioDynamics, Inc.
8.3 Medtronic, Inc.
8.4 Terumo Corporation
8.5 Johnson & Johnson
8.6 CareFusion Corporation
8.7 Animas Corporation
8.8 Baxter International Inc.
8.9 B. Braun Melsungen AG
8.10 I-Flow Corporation
8.11 F. Hoffmann-La Roche Ltd
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
